216 related articles for article (PubMed ID: 32426916)
1. Impact and production of Non-HLA-specific antibodies in solid organ transplantation.
Zhang X; Reinsmoen NL
Int J Immunogenet; 2020 Jun; 47(3):235-242. PubMed ID: 32426916
[TBL] [Abstract][Full Text] [Related]
2. Non-HLA antibodies against endothelial targets bridging allo- and autoimmunity.
Dragun D; Catar R; Philippe A
Kidney Int; 2016 Aug; 90(2):280-288. PubMed ID: 27188505
[TBL] [Abstract][Full Text] [Related]
3. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
Lefaucheur C; Viglietti D; Bouatou Y; Philippe A; Pievani D; Aubert O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Loupy A; Halloran PF; Dragun D
Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
[TBL] [Abstract][Full Text] [Related]
4. Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation.
Dragun D
Transplantation; 2008 Oct; 86(8):1019-25. PubMed ID: 18946337
[TBL] [Abstract][Full Text] [Related]
5. Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance.
Dragun D; Catar R; Philippe A
Curr Opin Organ Transplant; 2013 Aug; 18(4):430-5. PubMed ID: 23838648
[TBL] [Abstract][Full Text] [Related]
6. Association of vimentin antibody and other non-HLA antibodies with treated antibody mediated rejection in heart transplant recipients.
Zhang X; Levine R; Patel JK; Kittleson M; Czer L; Kobashigawa JA
Hum Immunol; 2020 Dec; 81(12):671-674. PubMed ID: 33041085
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients.
Reinsmoen NL; Lai CH; Heidecke H; Haas M; Cao K; Ong G; Naim M; Wang Q; Mirocha J; Kahwaji J; Vo AA; Jordan SC; Dragun D
Transplantation; 2010 Dec; 90(12):1473-7. PubMed ID: 21030904
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Impact of Non-HLA Antibodies in Solid Organ Transplantation.
Freischlag K; Pearl MH; Chambers ET
Clin Transpl; 2016; 32():31-43. PubMed ID: 28564521
[TBL] [Abstract][Full Text] [Related]
9. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients.
Fichtner A; Süsal C; Schröder C; Höcker B; Rieger S; Waldherr R; Westhoff JH; Sander A; Dragun D; Tönshoff B
Nephrol Dial Transplant; 2018 Jun; 33(6):1065-1072. PubMed ID: 29444269
[TBL] [Abstract][Full Text] [Related]
10. Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients.
Min JW; Lee H; Choi BS; Park CW; Yang CW; Kim YS; Choi YJ; Oh EJ; Chung BH
Ann Lab Med; 2018 Sep; 38(5):450-457. PubMed ID: 29797816
[TBL] [Abstract][Full Text] [Related]
11. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
[TBL] [Abstract][Full Text] [Related]
12. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss.
Giral M; Foucher Y; Dufay A; Duong Van Huyen JP; Renaudin K; Moreau A; Philippe A; Hegner B; Dechend R; Heidecke H; Brouard S; Cesbron A; Castagnet S; Devys A; Soulillou JP; Dragun D
Am J Transplant; 2013 Oct; 13(10):2567-76. PubMed ID: 23919486
[TBL] [Abstract][Full Text] [Related]
13. ARHGDIB and AT1R autoantibodies are differentially related to the development and presence of chronic antibody-mediated rejection and fibrosis in kidney allografts.
Betjes MGH; Sablik KA; Litjens NHR; Otten HG; de Weerd AE
Hum Immunol; 2021 Feb; 82(2):89-96. PubMed ID: 33358038
[TBL] [Abstract][Full Text] [Related]
14. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
[TBL] [Abstract][Full Text] [Related]
15. Influence of HLA disparity, immunosuppressive regimen used, and type of kidney allograft on production of anti-HLA class-I antibodies after transplant and occurrence of rejection.
Abdelnoor AM; Ajib R; Chakhtoura M; Daouk M; Medawar W; Uwaydah M; Sawah SI; Khauli RB
Immunopharmacol Immunotoxicol; 2009; 31(1):83-7. PubMed ID: 18752168
[TBL] [Abstract][Full Text] [Related]
16. Humoral immunity in hand transplantation: anti-HLA and non-HLA response.
Banasik M; Jabłecki J; Boratyńska M; Kamińska D; Kościelska-Kasprzak K; Bartoszek D; Chełmoński A; Hałoń A; Baran W; Klinger M
Hum Immunol; 2014 Aug; 75(8):859-62. PubMed ID: 24952209
[TBL] [Abstract][Full Text] [Related]
17. Role of non-HLA antibodies in organ transplantation.
Dragun D; Philippe A; Catar R
Curr Opin Organ Transplant; 2012 Aug; 17(4):440-5. PubMed ID: 22790079
[TBL] [Abstract][Full Text] [Related]
18. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies.
Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
Nephrology (Carlton); 2019 Mar; 24(3):347-356. PubMed ID: 29451342
[TBL] [Abstract][Full Text] [Related]
19. C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies.
Fuss A; Hope CM; Deayton S; Bennett GD; Holdsworth R; Carroll RP; Coates PT
Nephrology (Carlton); 2015 Jul; 20(7):467-73. PubMed ID: 25726938
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
Dragun D; Müller DN; Bräsen JH; Fritsche L; Nieminen-Kelhä M; Dechend R; Kintscher U; Rudolph B; Hoebeke J; Eckert D; Mazak I; Plehm R; Schönemann C; Unger T; Budde K; Neumayer HH; Luft FC; Wallukat G
N Engl J Med; 2005 Feb; 352(6):558-69. PubMed ID: 15703421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
